Turning nucleic acids into a disease-fighting force.

Today our research and development efforts are focused on developing targeted therapies around certain cancers and rare diseases for which limited treatments exist for patients—with the intention of unlocking new targets and applications for our medicines along the way. We believe that focusing within these therapeutic categories enables us to better continue to drive forward on the path to delivering solutions for patients.

To do this, we’re using two distinct technology platforms: toll-like receptor (TLR) immune modulation and our proprietary third-generation antisense platform based on our pioneering nucleic acid science. While we are currently focused on certain cancers and rare diseases, these technology platforms have much broader applicability, which enables opportunities for external partnerships in areas beyond our current focus areas.

  • Oncology

    We are developing our toll-like receptor agonist, IMO-2125 to treat certain solid tumors such as melanoma. We aim to dramatically improve the outcomes for patients suffering from these cancers. We are also developing our third-generation antisense platform and assessing it for oncology targets.

  • Rare Diseases

    We’re advancing toll-like receptor antagonism technology to address rare diseases with high unmet medical needs. Our goal is to develop novel therapies to treat these diseases, with improved long-term safety profiles and impact on disease remission.